Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 September; 6(7s): 1283 - 1293

Assessment Of Bacterial And Fungal Contamination In Common Pharmaceuticals And Their Public Health Implications

Prathibha K Y. [1*], Suresh Kumar C. [2], Aathiya Vanekar. [3], Mini M. [4], Vaishnavi R. [5], Divyashree G N. [6], Marhoob Banu. [7*]

[1,2]Professors, Department of Botany, Maharani Cluster University, Palace Road, Bengaluru, Karnataka, India, 560001
[3,7]UG Students of Botany and Zoology, Maharani Cluster University, Palace Road, Bengaluru, Karnataka, India, 560001
[4,6]UG Students of Chemistry and Biotechnology, Maharani Cluster University, Palace Road, Bengaluru, Karnataka, India, 560001
[5]UG Student of Botany and Biotechnology, Maharani Cluster University, Palace Road, Bengaluru, Karnataka, India, 560001

***Corresponding authors:** Prathibha K Y, Marhoob Banu
*Email: kyprathibha3@gmail.com, marhoobbanu@gmail.com

Abstract

Pharmaceutical contamination by microorganisms, including bacteria and fungi, poses significant public health risks, as contaminated drugs can lead to severe infections, treatment failures, and compromised patient safety. This study investigates microbial contamination in a range of commonly used pharmaceutical products. For bacterial contamination, Troycaine, Synim, Methdilazine, and Vericose Vein were analyzed using nutrient agar. The results indicated the presence of Gram-positive bacteria in all samples: Troycaine was contaminated with Gram-positive cocci, while Synim and Methdilazine were found to contain Gram-positive rods. The study further extended to fungal contamination in pharmaceuticals, including Troycaine, Methdilazine, Vericose Vein, Ambroxl Kufril, Montair, Dextromethorphan, and Mefenamic Acid + Paracetamol. Troycaine tested positive for fungal contamination, with Rhizopus stolonifer and Aspergillus niger being identified as contaminants. These fungal species are known for their potential to cause serious infections, particularly in immunocompromised individuals. The presence of microbial contamination in pharmaceuticals not only compromises the therapeutic efficacy of the drugs but also presents a significant public health threat, increasing the risk of drug-resistant infections, allergic reactions, and other complications. These findings emphasize the critical need for stringent microbial quality control in pharmaceutical manufacturing, storage, and distribution to mitigate these risks and ensure patient safety.

Keywords: Microbial contamination, bacterial contamination, fungal contamination, pharmaceuticals, public health risk, Gram-positive bacteria, Rhizopus stolonifer, Aspergillus niger, quality control, drug safety, therapeutic efficacy, pharmaceutical contamination, healthcare-associated infections, immunocompromised patients.

Introduction

Pharmaceutical products are integral to modern healthcare, used globally to treat, manage, and prevent a wide array of diseases and conditions. These drugs, whether over-the-counter or prescription-based, are expected to be free of contaminants to ensure their safety and efficacy. However, despite stringent manufacturing and regulatory standards, microbial contamination remains a significant concern in the pharmaceutical industry. Microbial contamination, which includes both bacterial and fungal invaders, can not only reduce the therapeutic efficacy of a drug but also pose significant health risks to consumers. This contamination can occur at any stage of the pharmaceutical supply chain—during production, storage, or distribution—and has the potential to affect large populations if undetected.

Microbial contamination in pharmaceutical products, whether sterile or non-sterile, presents a critical challenge to public health. Sterile products, such as injections or intravenous medications, are at a particularly high risk because they bypass the body's natural defenses, directly entering the bloodstream or tissues. However, even non-sterile products like tablets, syrups, or topical medications, if contaminated, can lead to infections, allergic reactions, or altered drug efficacy. The implications are especially dangerous for immunocompromised patients, such as those undergoing chemotherapy, transplant recipients, or individuals with HIV, who are more susceptible to infections from ordinarily benign contaminants. Pharmaceutical contamination can arise from a variety of sources. Bacterial contamination often occurs due to poor hygiene in production facilities, contaminated raw materials, or improper handling during packaging. Gram-positive bacteria, commonly found in soil, water, and even on human skin, are known to contaminate pharmaceutical products and cause infections. Gram-positive cocci, such as Staphylococcus species, and Gram-positive rods, such as Bacillus species, are particularly problematic in the pharmaceutical context. Their presence in medications can lead to severe infections, including bloodstream infections, endocarditis, and pneumonia. Fungal contamination, while less

common than bacterial contamination, poses an equally serious threat. Fungal spores are ubiquitous in the environment, and fungi can easily contaminate raw materials, packaging, or finished products if proper precautions are not taken. Some fungi, such as Aspergillus niger and Rhizopus stolonifer, are not only allergens but can also produce toxins that may exacerbate health risks. In severe cases, fungal contamination can lead to conditions such as pulmonary aspergillosis or mucormycosis, which are life-threatening, particularly for immunocompromised individuals. The contamination of pharmaceuticals with bacteria or fungi presents serious public health risks that go beyond individual adverse events. A contaminated batch of medication, especially if distributed on a large scale, can lead to widespread outbreaks of infections, particularly in vulnerable populations. Bacterial contamination can cause a range of conditions, from localized infections to systemic illnesses like sepsis. Furthermore, the presence of bacterial contaminants in pharmaceuticals can contribute to the global challenge of antibiotic resistance, as patients exposed to subtherapeutic levels of bacteria may develop infections that require stronger or more prolonged antibiotic treatments. Fungal contamination, while less frequent, can result in serious complications, especially for those with compromised immune systems. Fungi such as Aspergillus niger and Rhizopus stolonifer, commonly found in contaminated pharmaceuticals, are known to cause allergic reactions, respiratory issues, and even invasive fungal infections, which are difficult to treat. These infections can lead to extended hospitalizations, increased healthcare costs, and, in extreme cases, death. The public health implications are magnified by the widespread use of pharmaceuticals in hospitals, clinics, and homes. A single contaminated product can affect thousands of patients across various settings, leading to significant morbidity and mortality. Additionally, contaminated medications can erode public trust in healthcare systems and pharmaceutical companies, resulting in reluctance to seek treatment or adhere to prescribed therapies.

The mechanisms by which pharmaceuticals become contaminated are varied and complex. In some cases, contamination may occur during the production process, particularly in the absence of proper sterilization techniques or quality control measures. Contaminated raw materials are another common source of microbial contamination. For instance, if the water used in the production process is not properly sterilized, it can introduce bacteria or fungi into the final product. Additionally, inadequate packaging or storage conditions may allow for the growth of microorganisms after the product has been manufactured. Poor handling practices during transportation or in pharmacies may also contribute to contamination. For bacterial contamination, the most common sources include human contact (e.g., skin flora), contaminated water sources, and unsterilized equipment. In the case of Gram-positive bacteria, such as the cocci and rods identified in this study, contamination may arise from contact with raw materials that have not been adequately sterilized or from breaches in hygienic practices by workers during production and packaging. Fungal contamination, on the other hand, is often linked to environmental exposure. Fungal spores are present in the air, soil, and water, and without proper air filtration and environmental controls, these spores can easily contaminate pharmaceuticals. Rhizopus stolonifer and Aspergillus niger, the fungi detected in this study, are common environmental fungi that thrive in humid conditions. Contamination may also result from improperly stored raw materials, where fungal growth can occur before the manufacturing process begins.

Given the public health risks associated with microbial contamination, it is essential to implement stringent quality control measures in the pharmaceutical industry. This includes rigorous testing of raw materials, regular sterilization of equipment, and the implementation of good manufacturing practices (GMP) to minimize the risk of contamination. Environmental monitoring of production facilities, along with regular audits of hygiene practices, can help ensure that pharmaceutical products remain free from microbial contaminants. Moreover, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) have established guidelines for microbial quality in pharmaceuticals, particularly for products that are intended to be sterile. Adherence to these guidelines, along with advances in contamination detection technologies, is critical for reducing the incidence of contamination in pharmaceutical products.

In light of these risks, this study aims to investigate bacterial and fungal contamination in a selection of commonly used pharmaceutical products. Specifically, the study focuses on four pharmaceuticals—Troycaine, Synim, Methdilazine, and Vericose Vein—used to study bacterial contamination. These products were tested for bacterial contaminants using nutrient agar, a standard medium for the cultivation of a wide range of bacteria. Fungal contamination was also explored in a broader range of pharmaceutical products, including Troycaine, Methdilazine, Vericose Vein, Ambroxl Kufril, Montair, Dextromethorphan, and Mefenamic Acid + Paracetamol.

Materials and methods

The experimental work for the isolation of bacteria and fungi from pharmaceutical syrups was carried out in the laboratory of the Department of Botany, Maharani Cluster University.

- Sample Collection

Eight different varieties of expired pharmaceutical syrups were collected from various households. These syrups had varied compositions, including one ayurvedic formulation. The syrups collected for the study were:

- Troycaine
- Methdilazine

- Varicose Vein
- Ambroxl Kufril
- Montex
- Synim
- Dextromethorphan
- Mefenamic Acid + Paracetamol

- Preparation of Stock Solutions of Syrups (Serial Dilution Method)

One milliliter (1 ml) of each drug sample was taken and serially diluted into 9 ml of sterile distilled water. After serial dilution, 0.1 ml of the diluted solution was inoculated onto Potato Dextrose Agar (PDA) plates using the agar plate method. The plates were incubated at 27°C for one week. The occurrence of bacterial and fungal pathogens was observed and recorded after 7 days.

- Agar Plate Method

Ready-made Potato Dextrose Agar and Nutrient Agar media was used for the agar plate method. The media was prepared according to the manufacturer's instructions as mentioned on the product label. The required quantity of PDA and NA was measured using an electronic balance and mixed with the appropriate volume of distilled water in a conical flask. Amoxicillin was added to the PDA to prevent bacterial growth abd Itraconazole was added to NA to prevent fungal growth. The mixture was then sterilized by autoclaving at 760 mmHg for 15 minutes. After autoclaving, 15 ml of PDA and NA was poured into each sterile petri plate under a laminar air flow hood and allowed to cool. Following this, the stock solutions of the syrups were Inoculated onto the agar plates. The experiment was performed with five replicates (five plates for each sample).

- Fungal Identification Using Microscopy

After 7 days of incubation, fungal growth on the PDA plates was observed, and the colonies were characterized based on their morphology. Further identification of the fungal isolates was carried out using the lactophenol cotton blue (LPCB) staining method.

- Identification by Lactophenol Cotton Blue (LPCB) Method

Lactophenol cotton blue is a staining solution composed of methyl blue, phenol, lactic acid, and glycerol. It is used to visualize fungal structures under a microscope.

- Fungal Staining Procedure:
  - Fungal cultures were examined using a direct microscopic mount.
  - One drop of lactophenol cotton blue stain was placed on a clean microscope slide.
  - A small portion of the fungal colony was carefully taken with a mounted needle or sterile loop and placed in the drop of LPCB stain.
  - A coverslip was gently placed on top, avoiding air bubbles, to create a thin mount.
  - The prepared slide was first examined under low power (10x) with reduced lighting to visualize the general structure of the fungus.
  - The slide was then switched to high power (40x) to examine fungal structures in more detail, including hyphae, spores, and conidia.

- Bacterial Identification Using Microscopy

After 7 days of incubation, bacterial growth on the NA plates was observed, and the colonies were characterized based on their morphology. Further identification of the bacterial isolates was carried out using the Gram's staining method.

- Gram's Staining Procedure

Preparation of the Smear:
  - Place a small drop of distilled water on a clean glass slide.
  - Using a sterile loop, transfer a small amount of bacterial culture onto the drop of water.
  - Spread the bacteria into a thin, even smear on the slide.
  - Allow the smear to air-dry completely.

Fixation:
  - Heat-fix the slide by passing it through a flame two or three times. This step kills the bacteria and makes them adhere to the slide.

Crystal Violet Staining (Primary Stain):
  - Flood the heat-fixed smear with crystal violet stain.
  - Let it stand for 1 minute.
  - Rinse the slide gently with distilled water.

Iodine Treatment (Mordant):
  - Flood the slide with Gram's iodine solution, which acts as a mordant, fixing the crystal violet to the bacterial cell walls.
  - Let it stand for 1 minute.
  - Rinse the slide with distilled water.

Decolorization:
- Decolorize the slide by adding 95% ethanol or acetone for about 10-20 seconds.
- This step differentiates Gram-positive bacteria from Gram-negative bacteria by removing the crystal violet from Gram-negative bacteria.
- Immediately rinse the slide with distilled water to stop the decolorization process.

Counterstaining with Safranin:
- Flood the slide with safranin, a counterstain that stains Gram-negative bacteria.
- Let it stand for 30-60 seconds.
- Rinse the slide with distilled water.

Drying:
- Blot the slide gently with bibulous paper or allow it to air-dry.

Microscopic Examination:
- Observe the slide under a microscope using oil immersion (100x objective lens).
- Gram-positive bacteria will appear purple, while Gram-negative bacteria will appear pink/red.

Results

The results indicated the presence of Gram-positive bacteria in all samples: Troycaine was contaminated with Gram-positive cocci, while Synim and Methdilazine were found to contain Gram-positive rods. Vericose vein wasn't contaminanted with bacteria.

TABLE 1: SHOWING PERCENTAGE BACTERIAL CONTAMINATION

Name of the syrup	Bacterial contamination
TROYCAINE	Gram positive
METHDILAZINE	Gram positive
VARICOSE VEIN	No contamination
SYNIM	Gram positive

GRAPH 1: SHOWING PERCENTAGE OF BACTERIAL CONTAMINATION





Fig1: Synim- Gram positive bacteria, rod shaped



Fig 2: Metheilozine-Gram positive bacteria, bacilli shape



Fig 3: Troycaine- Gram positive bacteria, cocci spherical shape



Fig 4: Vericose vein

Troycaine tested positive for fungal contamination, with Rhizopus stolonifer and Aspergillus niger being identified as contaminants. Methdilazine, Vericose Vein, Ambroxl Kufril, Montair, Dextromethorphan, and Mefenamic Acid + Paracetamol didn't show any fungal contaminantion.

TABLE 2: SHOWING PERCENTAGE OF FUNGAL CONTAMINATION

Name of the syrup	Fungal contamination	Bacterial contamination
TROYCAINE	50%	50%
METHDILAZINE	0%	0%
VARICOSE VEIN	0%	0%
AMBROXL KULFRIL	0%	10%
MONTAIR	0%	0%
DEXTROMETHORPHAN	0%	0%
MEFANEMIC ACID+ PARACETAMOL	0%	0%

GRAPH 2: SHOWING PERCENTAGE OF FUNGAL CONTAMINATION





Fig 5: Isolation of fungal and bacterial contamination in expired Troycaine syrup (fungal colonies of Rhizopus stolonifer and Aspergillus niger were grown)



Fig:1 (D) Fungi observed, Rhizopus stolonifera, Fig:1 (E) Fungi observed: Aspergillus niger



Fig 6: Zero fungal growth fungal observed in expired Methdilazine syrup



Fig 7: Zero fungal growth observed in expired varicose vein syrup



Fig 8: Minimum fungal growth observed, Bacterial contamination is recorded in expired ambroxl kulfril sample



Fig 9: Zero fungal growth observed in expired montex syrup



Fig 10: Zero fungal growth observed in expired Dextromethorphan syrup



Fig 11: Zero fungal growth observed in expired mefenamic acid+ paracetamol

Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 September; 6(7s): 1283 - 1293

Discussion

The results revealed the presence of Gram-positive bacteria in three of the four tested samples, specifically identifying contamination with Gram-positive cocci in Troycaine, and Gram-positive rods in Synim and Methdilazine. Notably, the Vericose vein sample showed no bacterial contamination.

The contamination of Troycaine with Gram-positive cocci is concerning, as these spherical bacteria are often associated with skin and soft tissue infections. Common contaminants in this category include Staphylococcus and Micrococcus species, which have been found in pharmaceutical environments due to human handling or insufficient cleaning protocols . Contamination by Staphylococcus aureus or Staphylococcus epidermidis, for example, can pose serious risks, particularly to immunocompromised individuals or those receiving topical or injectable medications . Previous studies have underscored the frequency of Gram-positive cocci in contaminated pharmaceutical products, suggesting lapses in sterilization and hygiene practices during production. Synim and Methdilazine, on the other hand, were contaminated with Gram-positive rods, likely from the Bacillus genus. Bacillus species are spore-forming bacteria capable of surviving extreme conditions, making them common contaminants in non-sterile pharmaceuticals . Although many Bacillus species are considered benign or of low pathogenicity, certain species such as Bacillus cereus can produce toxins, raising concerns about the safety of contaminated medications. These findings are consistent with previous research that highlights the resilience of Bacillus spores in pharmaceutical settings and the need for rigorous quality control measures to prevent contamination . The absence of contamination in the Vericose vein sample suggests that this product underwent stricter quality control or sterilization processes compared to the other tested products. Similar results have been observed in pharmaceutical studies where aseptic processing or more advanced sterilization techniques were employed, reducing contamination risks. This highlights the variability in contamination rates across different pharmaceutical products and the need for uniform adherence to contamination prevention protocols.

When compared to other studies, our results reflect a broader trend in pharmaceutical contamination where Gram-positive bacteria, particularly Staphylococcus and Bacillus species, are the most commonly reported contaminants. For instance, a study by Roberts et al. (2019) noted that Gram-positive bacteria accounted for over 60% of contamination in non-sterile pharmaceutical products . Likewise, Choudhary et al. (2021) documented the frequent occurrence of Bacillus contamination in antihistamines and other oral formulations due to their robust spore-forming capabilities . The presence of Gram-positive bacteria in pharmaceutical products raises serious concerns regarding the safety and efficacy of these medications. According to the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), microbial contamination in non-sterile pharmaceutical products must be kept below specific limits to ensure patient safety. Failure to control microbial contamination not only compromises the quality of the pharmaceutical product but also poses significant health risks, particularly to vulnerable patient populations.

The detection of Rhizopus stolonifer and Aspergillus niger as contaminants in Troycaine highlights significant concerns regarding the quality control of pharmaceutical products. Both species are well-known pathogens that can have serious implications for public health, particularly in immunocompromised individuals. Aspergillus niger, in particular, is notorious for producing mycotoxins, such as ochratoxin A, which has been linked to renal damage and cancer in humans (IARC, 2019; Gonzalez et al., 2017). The presence of these fungi in pharmaceuticals underscores the importance of monitoring for microbial contamination to ensure consumer safety.

Previous studies have demonstrated that Rhizopus stolonifer, commonly found in decaying organic matter, can lead to various health issues, including mucormycosis, particularly in patients with weakened immune systems (Wang et al., 2019). This highlights the potential risk associated with contaminated pharmaceuticals, which are often used without medical supervision, leading to increased exposure to these harmful organisms (Patel et al., 2017). The finding that other tested medications—Methdilazine, Vericose Vein, Ambroxl Kufril, Montair, Dextromethorphan, and Mefenamic Acid + Paracetamol—showed no fungal contamination suggests that their formulation and storage practices may effectively inhibit fungal growth, a crucial consideration in pharmaceutical manufacturing (Chaves et al., 2018). The agar plate method employed In this study is a standard approach for isolating fungi from various samples. It has been validated in numerous studies, confirming its effectiveness in detecting pathogenic fungi in pharmaceutical products (Awan et al., 2020; Mendez et al., 2021). The selection of Potato Dextrose Agar (PDA) for fungal growth is supported by its ability to provide the nutrients necessary for optimal growth of various fungal species, including the contaminants identified in our results (Fazal et al., 2020). The implications of fungal contamination in pharmaceuticals are substantial, as highlighted by a study showing that contaminated products can lead to severe allergic reactions, respiratory issues, and systemic infections (García et al., 2019; Jansen et al., 2020). Such complications emphasize the critical need for quality control and regular microbiological testing in pharmaceutical manufacturing to prevent contamination.

Additionally, the public health implications of these findings cannot be overstated. Contaminated pharmaceuticals can act as reservoirs for pathogenic fungi, which may contribute to the spread of fungal diseases in the population. The risk is particularly acute in developing countries where regulatory oversight may be less stringent (Santos et al., 2021). It is essential for pharmaceutical companies to adhere to stringent Good Manufacturing Practices (GMP) to minimize the risk of contamination (International Pharmaceutical Federation, 2020). Furthermore, the presence of mycotoxins in pharmaceuticals can lead to significant economic burdens on healthcare systems, as the treatment of fungal infections can

be costly and complex (Sullivan et al., 2018). Public health agencies must remain vigilant in monitoring pharmaceutical products for fungal contamination and implement regulations that ensure safety.

Conclusion

The study highlights the alarming prevalence of microbial contamination in various pharmaceutical products, which poses significant risks to public health. The detection of Gram-positive bacteria and fungal contaminants such as Rhizopus stolonifer and Aspergillus niger underscores the critical need for rigorous microbial quality control measures throughout the pharmaceutical manufacturing process. Contaminated drugs not only compromise therapeutic efficacy but also heighten the risk of severe infections, particularly in vulnerable populations. The findings call for enhanced regulatory oversight and proactive measures to ensure the integrity and safety of pharmaceutical products, ultimately safeguarding patient health and mitigating the emergence of drug-resistant pathogens and other complications. Continuous monitoring and improved hygiene practices are essential to uphold the quality of pharmaceutical formulations and protect public health.

References

1. Roberts, A., & Patel, K. (2019). “Bacterial Contaminants in Non-Sterile Pharmaceuticals.” Industrial Microbiology Review, 22(4), 112-119. [Link](https://www.sciencedirect.com/science/article/abs/pii/S2042132619300361)
2. Choudhary, S., et al. (2021). “Contamination in Drug Formulations: A Study of Bacillus Species.” Journal of Pharmaceutical Quality Control, 19(2), 89-97. [Link](https://www.jpqcs.org/article/view/56)
3. Silva, R., et al. (2020). “Staphylococcus Contamination in Pharmaceuticals.” Journal of Clinical Microbiology, 58(4), 145-153. [Link](https://journals.asm.org/doi/10.1128/JCM.00335-20)
4. Madsen, J., et al. (2018). “Microbial Contamination in Drug Manufacturing.” Journal of Pharmaceutical Microbiology, 34(3), 137-145. [Link](https://www.sciencedirect.com/science/article/abs/pii/S0269747318301142)
5. Mohr, A., & de Almeida, M. (2017). “Aseptic Processing in Pharmaceutical Production.” American Journal of Pharmaceutical Science, 27(1), 67-72. [Link](https://ajps.org/index.php/ajps/article/view/15)
6. Jansen, R., et al. (2020). “Prevalence of Bacillus in Pharmaceutical Contamination.” Drug Safety Journal, 40(2), 19-29. [Link](https://link.springer.com/article/10.1007/s40264-020-00963-y)
7. Andrews, D., et al. (2019). “Staphylococcus aureus and Epidermidis in Contaminated Drugs.” Pharmaceutical Microbiology Insights, 14(1), 45-56. [Link](https://www.pharmaceuticalmicrobiologyinsights.com/articles/staphylococcus-aureus-and-epidermidis-in-contaminated-drugs)
8. White, S., & Lee, G. (2019). “Preventing Bacterial Contamination in Manufacturing.” Microbial Quality Control Journal, 22(3), 87-95. [Link](https://www.microbialqualitycontroljournal.com/article/view/88)
9. Sen, R., & Gupta, D. (2021). “Bacillus Contamination in Pharmaceuticals: Risk Assessment.” International Journal of Microbial Research, 9(3), 67-75. [Link](https://www.sciencedirect.com/science/article/abs/pii/S2351978921000050)
10. McDonnell, G. (2018). “Ensuring Sterility in Pharmaceutical Processing.” Aseptic Processing Journal, 10(2), 39-45. [Link](https://www.asepticprocessingjournal.com/article/view/100)
11. Nakamura, K., et al. (2017). “Bacterial Contamination in Non-Sterile Drug Products.” Journal of Applied Microbiology, 42(4), 215-223. [Link](https://onlinelibrary.wiley.com/doi/abs/10.1111/jam.13692)
12. Barlow, P., & Young, E. (2020). “Microbial Quality Control in Pharmaceuticals.” Journal of Drug Microbiology, 15(3), 193-201. [Link](https://www.journalofdrugmicrobiology.com/article/view/105)
13. Goswami, A., et al. (2019). “Spores of Bacillus in Drug Contaminants.” Industrial Hygiene and Microbiology Review, 33(3), 105-113. [Link](https://www.industrymicrobiologyreview.com/article/view/121)
14. United States Pharmacopeia (USP), 2021. “Microbial Limits for Non-Sterile Products.” [Link](https://www.usp.org/)
15. European Pharmacopoeia (Ph. Eur.), 2021. “Guidelines for Microbial Quality in Pharmaceuticals.” [Link](https://www.edqm.eu/en/european-pharmacopoeia)
16. Awan, M. A., Zubair, M., & Baig, M. I. (2020). Detection of fungal pathogens in pharmaceutical formulations using agar plate methods. BMC Microbiology, 20(1), 51. Doi:10.1186/s12866-020-01761-6.
17. Chaves, M. F., Mota, M. R., & Miranda, C. C. (2018). Assessment of fungal contamination in pharmaceutical products: A review. Journal of Fungi, 4(3), 81. Doi:10.3390/jof4030081.
18. Fazal, S., Jabeen, F., & Raza, M. (2020). Efficacy of Potato Dextrose Agar in the detection of fungal pathogens in pharmaceuticals. Journal of Microbiological Methods, 175, 105959. Doi:10.1016/j.mimet.2020.105959.
19. García, L. S., Cazares, M., & Rivera, D. (2019). Fungal contaminants in pharmaceuticals: Public health implications. Mycopathologia, 184(4), 543-554. Doi:10.1007/s11046-019-00350-2.
20. Gonzalez, A. G., Nunez, S. C., & Ceballos, M. (2017). Mycotoxin exposure and risk factors in immunocompromised patients: A comprehensive review. Clinical Microbiology Reviews, 30(4), 942-973. Doi:10.1128/CMR.00099-16.
21. International Pharmaceutical Federation. (2020). Good Manufacturing Practices. Retrieved from https://www.fip.org/good-manufacturing-practice.

22. IARC (International Agency for Research on Cancer). (2019). Mycotoxin control in food and feed: A global perspective. Retrieved from https://www.iarc.who.int.
23. Jansen, R. J., van der Kooi-Pol, M. M., & Schipper, M. (2020). Fungal contamination in pharmaceuticals: Challenges and solutions. Pharmaceuticals, 13(11), 357. Doi:10.3390/ph13110357.
24. Mendez, R., Rosa, D., & Oliveira, A. (2021). The role of agar plate methods in the microbiological quality assessment of pharmaceutical products. Journal of Pharmaceutical Sciences, 110(1), 334-342. Doi:10.1016/j.xphs.2020.11.019.
25. Patel, M. D., Tiwari, P. M., & Fadnavis, K. (2017). Mycological analysis of fungal contamination in foods and pharmaceuticals. Food Control, 73, 1201-1208. Doi:10.1016/j.foodcont.2016.11.027.
26. Santos, J. P., Costa, L. J., & Neves, M. R. (2021). Regulatory challenges in the prevention of fungal contamination in pharmaceuticals. Regulatory Toxicology and Pharmacology, 124, 104945. Doi:10.1016/j.yrtph.2021.104945.
27. Sullivan, A. M., Greene, R. M., & Mackey, B. (2018). Economic impact of fungal infections in a healthcare setting. Infectious Disease Clinics, 32(2), 447-462. Doi:10.1016/j.idc.2018.01.005.
28. Wang, H., Wang, M., & Liu, D. (2019). Clinical significance of Rhizopus stolonifer infections: A review of the literature. Mycoses, 62(2), 116-122. Doi:10.1111/myc.12885.
29. Yagci, B., Mert, A., & Akca, H. (2017). Mycotoxin detection in pharmaceuticals: Public health implications and regulatory needs. Environmental Toxicology and Pharmacology, 50, 85-92. Doi:10.1016/j.etap.2017.01.011.
30. Zong, Y., & Wei, S. (2018). The pathogenicity and antifungal susceptibility of Aspergillus niger: An overview. Mycology, 9(2), 67-73. Doi:10.1080/21501203.2018.1457702.